Opendata, web and dolomites

LIFT SIGNED

Liquid Foam Therapy (LIFT) for Acute Respiratory Distress Syndrome (ARDS)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LIFT project word cloud

Explore the words cloud of the LIFT project. It provides you a very rough idea of what is the project "LIFT" about.

broadly    inner    depletion    1ml    vitro    advocate    printed    medicine    excised    business    microfabricated    models    expand    vivo    respiratory    replacement    shift    annually    pools    animal    40    extend    expertise    therapy    mortality    nebulizers    syndrome    optimize    homogeneously    paradigm    therapeutic    inflammatory    3d    foam    babies    stem    reduces    regions    children    team    biomedical    pneumonia    injury    adults    chest    ex    disease    chronic    idiopathic    treatment    demonstrated    people    formulation    engineering    carrier    leaving    leveraged    untreated    obstructive    newborn    inhalation    overcome    intensive    run    experiments    tension    distress    acute    drains    pulmonary    airway    hurdles    lift    administration    srt    gravity    span    pending    133    ipf    255    lung    coating    pig    liquid    neonates    care    surfactant    groups    hr    anesthetized    therapies    fibrosis    instillations    fluoroscopy    surface    patients    feasibility    device    caused    saving    aerosols    age    drowning    fail    brings    distributes    clinical    100ml    lungs    ards    doses    life    sepsis    poc    rates    construct    head    copd    cell    procedure    abundance    endotracheal    larger    bridges    inadequate    treat    lt    lay    meanwhile    patent    forces    small   

Project "LIFT" data sheet

The following table provides information about the project.

Coordinator
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY 

Organization address
address: SENATE BUILDING TECHNION CITY
city: HAIFA
postcode: 32000
website: www.technion.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY IL (HAIFA) coordinator 150˙000.00

Map

 Project objective

Acute Respiratory Distress Syndrome (ARDS) is an inflammatory lung condition caused e.g. by sepsis, pneumonia and head or chest injury, affecting annually 133,000 people in Europe and 255,000 in the US. ARDS is characterized by the depletion of the lungs’ inner liquid coating (pulmonary surfactant), which reduces surface tension forces and allows the lungs to expand. Patients span across all age groups and lay anesthetized in the intensive care unit with mortality rates at 40%. Although surfactant replacement therapy (SRT) is a life-saving procedure in newborn neonates, current administration methods to treat adults and even children remain inadequate. Endotracheal surfactant liquid instillations used in babies fail in larger lungs: liquid drains into pools, drowning these lung regions while leaving others untreated. Meanwhile, inhalation aerosols can only deliver small doses (<1ml/hr for nebulizers), far from the required ~100ml of surfactant. To overcome such hurdles, we advocate using liquid foam as a surfactant carrier to the lungs, i.e. LIquid Foam Therapy (LIFT). Foam is weakly affected by gravity, distributes homogeneously within lungs and in abundance. LIFT brings a paradigm shift in SRT, and more broadly, in the field of therapeutic pulmonary delivery. Our team bridges expertise in clinical ARDS treatment in neonates, pulmonary medicine, biomedical engineering and business. Together, we have demonstrated the feasibility of our patent pending technology, both in vitro in 3D printed and microfabricated airway models, and ex vivo in excised pig lungs using fluoroscopy. In this PoC, we will optimize the foam formulation, design and construct a delivery device, and run pre-clinical in vivo animal experiments. LIFT has the potential to extend far beyond ARDS treatment and be leveraged for other lung therapies, such as stem cell delivery directly to the lungs to treat Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIFT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIFT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More